Scanlon Susan E, Glazer Peter M
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA; Department of Experimental Pathology, Yale University School of Medicine, New Haven, CT, USA.
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA; Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
DNA Repair (Amst). 2015 Aug;32:180-189. doi: 10.1016/j.dnarep.2015.04.030. Epub 2015 May 1.
Hypoxia, as a pervasive feature in the microenvironment of solid tumors, plays a significant role in cancer progression, metastasis, and ultimately clinical outcome. One key cellular consequence of hypoxic stress is the regulation of DNA repair pathways, which contributes to the genomic instability and mutator phenotype observed in human cancers. Tumor hypoxia can vary in severity and duration, ranging from acute fluctuating hypoxia arising from temporary blockages in the immature microvasculature, to chronic moderate hypoxia due to sparse vasculature, to complete anoxia at distances more than 150 μM from the nearest blood vessel. Paralleling the intra-tumor heterogeneity of hypoxia, the effects of hypoxia on DNA repair occur through diverse mechanisms. Acutely, hypoxia activates DNA damage signaling pathways, primarily via post-translational modifications. On a longer timescale, hypoxia leads to transcriptional and/or translational downregulation of most DNA repair pathways including DNA double-strand break repair, mismatch repair, and nucleotide excision repair. Furthermore, extended hypoxia can lead to long-term persistent silencing of certain DNA repair genes, including BRCA1 and MLH1, revealing a mechanism by which tumor suppressor genes can be inactivated. The discoveries of the hypoxic modulation of DNA repair pathways have highlighted many potential ways to target susceptibilities of hypoxic cancer cells. In this review, we will discuss the multifaceted hypoxic control of DNA repair at the transcriptional, post-transcriptional, and epigenetic levels, and we will offer perspective on the future of its clinical implications.
缺氧作为实体瘤微环境中的一个普遍特征,在癌症进展、转移以及最终的临床结局中起着重要作用。缺氧应激的一个关键细胞后果是对DNA修复途径的调控,这导致了在人类癌症中观察到的基因组不稳定和突变体表型。肿瘤缺氧的严重程度和持续时间各不相同,从由于未成熟微血管的临时阻塞引起的急性波动缺氧,到由于血管稀疏导致的慢性中度缺氧,再到距离最近血管超过150微米处的完全缺氧。与肿瘤内缺氧的异质性平行,缺氧对DNA修复的影响通过多种机制发生。急性缺氧主要通过翻译后修饰激活DNA损伤信号通路。在较长的时间尺度上,缺氧导致大多数DNA修复途径的转录和/或翻译下调,包括DNA双链断裂修复、错配修复和核苷酸切除修复。此外,长时间的缺氧可导致某些DNA修复基因(包括BRCA1和MLH1)的长期持续沉默,揭示了肿瘤抑制基因可能被灭活的一种机制。DNA修复途径的缺氧调节的发现突出了许多针对缺氧癌细胞易感性的潜在方法。在这篇综述中,我们将讨论在转录、转录后和表观遗传水平上对DNA修复的多方面缺氧控制,并对其临床意义的未来提供展望。